<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937881</url>
  </required_header>
  <id_info>
    <org_study_id>CO-US-412-6091</org_study_id>
    <nct_id>NCT04937881</nct_id>
  </id_info>
  <brief_title>PK of TAF and TDF for PrEP in Pregnant and Postpartum Women</brief_title>
  <acronym>PrEP-PP PK</acronym>
  <official_title>Comparison of Pharmacokinetics of Tenofovir Alafenamide (TAF) With Tenofovir Disoproxil (TDF) in Pregnant and Postpartum Women and Their Infants in PrEP-PP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Desmond Tutu HIV Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will establish benchmarks of TFV-DP concentrations as measures of adherence&#xD;
      following daily dosing with Tenofovir Alafenamide (TAF) compared with Tenofovir Disoproxil&#xD;
      Fumarate (TDF) during pregnancy and postpartum. Study Investigators will recruit from an&#xD;
      ongoing observational cohort study in Cape Town, South Africa, PrEP-PP (recruitment ongoing&#xD;
      through July, 2021; NIMH R01MH116771; PI Coates &amp; Myer). Findings form this PK sub-study will&#xD;
      be used to inform future PrEP in pregnancy and postpartum studies and develop benchmarks of&#xD;
      the relative PK between TDF and TAF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will establish benchmarks of TFV-DP concentrations as measures of adherence&#xD;
      following daily dosing with Tenofovir Alafenamide (TAF) compared with Tenofovir Disoproxil&#xD;
      Fumarate (TDF) during pregnancy and postpartum. Study Investigators will recruit from an&#xD;
      ongoing observational cohort study in Cape Town, South Africa, PrEP-PP (recruitment ongoing&#xD;
      through July, 2021; NIMH R01MH116771; PI Coates &amp; Myer). Findings form this PK sub-study will&#xD;
      be used to inform future PrEP in pregnancy and postpartum studies and develop benchmarks of&#xD;
      the relative PK between TDF and TAF.&#xD;
&#xD;
      Study aims. (1) To establish benchmarks of TFV-DP concentrations as measures of adherence&#xD;
      following daily dosing with TAF vs TDF in pregnancy and again in postpartum; (2) To compare&#xD;
      the difference of TFV-DP within TDF and TAF for pregnancy vs. postpartum, and to establish&#xD;
      adherence benchmarks of levels of TFV in breastmilk in postpartum women and compare with TDF&#xD;
      sample.&#xD;
&#xD;
      The study will take place in an urban township in Cape Town (Gugulethu) with high HIV&#xD;
      incidence that spans the different socioeconomic, cultural, and ethnic groups in South&#xD;
      Africa. We selected this community because of the high HIV prevalence there in pregnant and&#xD;
      breastfeeding women, and because of the high number of mothers visiting every month for ANC&#xD;
      and labour/delivery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This phase III study is a randomised control trial (RCT) of 50 pregnant women who will be recruited at first antenatal visit (ANC) from the Gugulethu Midwife and Obstetrics Unit.&#xD;
Participants will be randomized into the TDF vs TAF arm:&#xD;
TDF Arm: Women will receive a fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF) administered once daily under direct observation for 8 weeks during pregnancy and again for 8 weeks in postpartum period TAF Arm: Fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF) administered once daily under direct observation for 8 weeks during pregnancy and again for 8 weeks in postpartum period Women will provide their own controls, providing pregnant and postpartum samples.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tenofovir diphosphate (TDF-DP) concentrations in plasma and interceullalar levels in pregnant and pospartum women on daily PrEP</measure>
    <time_frame>8 weeks after directly observed treatment</time_frame>
    <description>Plasma and intracellular levels of tenofovir and TFV-DP in the PrEP setting, comparing the drugs TAF to TDF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tenofovir diphosphate (TDF-DP) concentrations in plasma and interceullalar levels comparing pregnancy against postpartum women</measure>
    <time_frame>8 weeks after directly observed treatment</time_frame>
    <description>Plasma and intracellular levels of tenofovir and plasma TDF-DP in antenatal and postpartum groups intra-individual comparisons.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hiv</condition>
  <arm_group>
    <arm_group_label>TAF arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF) delivered under direct observation for 8 weeks during pregnancy and 8 weeks in postpartum period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF) delivered under direct observation for 8 weeks during pregnancy and 8 weeks in postpartum period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir alafenamide</intervention_name>
    <description>Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF)</description>
    <arm_group_label>TAF arm</arm_group_label>
    <other_name>TAF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF)</description>
    <arm_group_label>TDF arm</arm_group_label>
    <other_name>TDF or Truvada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt;18 years old&#xD;
&#xD;
          2. confirmed HIV-negative (confirmed with a 4th generation antigen HIV test) at time of&#xD;
             study entry&#xD;
&#xD;
          3. intend on giving birth in the MOU facility&#xD;
&#xD;
          4. confirmed to be 14-24 weeks pregnant&#xD;
&#xD;
          5. without psychiatric or medical contraindications to PrEP&#xD;
&#xD;
          6. estimated creatinine clearance (CrCI) &gt;60mL/min&#xD;
&#xD;
          7. resides close to clinic (&lt;10km)&#xD;
&#xD;
          8. has a smart phone that can take video footage (with data bundle from study)&#xD;
&#xD;
          9. agrees to provide video phone footage of taking a pill a day for 8 weeks during&#xD;
             pregnancy and again for 8 weeks in postpartum period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Individuals not meeting the above criteria or meeting any of the following criteria will be&#xD;
        excluded:&#xD;
&#xD;
          1. Concurrent enrolment in another HIV-1 vaccine or prevention trial&#xD;
&#xD;
          2. History of renal disease&#xD;
&#xD;
          3. Current clinical diagnosis of hypertension&#xD;
&#xD;
          4. Exhibiting psychotic symptoms&#xD;
&#xD;
          5. Currently or history of taking an anti-psychotic medication&#xD;
&#xD;
          6. Positive Hepatitis B surface antigen (HBsAg) test on screening&#xD;
&#xD;
          7. History of bone fracture not related to trauma&#xD;
&#xD;
          8. Any other medical, psychiatric or social condition which in the opinion of the&#xD;
             investigators would affect the ability to consent and/or participate in the study&#xD;
&#xD;
          9. Any maternal or fetal complication, obstetric or medical, detected during routine care&#xD;
             or study procedures that requires referral of pregnant or postpartum women/infants to&#xD;
             secondary or tertiary obstetric or medical care.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Landon Myer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dvora Joseph-Davey, PhD</last_name>
    <phone>+27 829430578</phone>
    <email>dvoradavey@ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Orrell, PhD</last_name>
    <phone>+27 829430578</phone>
    <email>catherine.orrell@dthf.org.za</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gugulethu Midwife Obstetric Unit</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Dvora Joseph Davey, PhD, MPH</investigator_full_name>
    <investigator_title>Assistant Professor, Epidemiology</investigator_title>
  </responsible_party>
  <keyword>pre-exposure prophylaxis</keyword>
  <keyword>PrEP</keyword>
  <keyword>pregnancy</keyword>
  <keyword>postpartum</keyword>
  <keyword>HIV prevention</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>TAF</keyword>
  <keyword>TDF</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

